In addition, patients receiving nilotinib demonstrated a lower rate of progression to the accelerated or blast stage of CML. Also in this study, the 5-year OS and PFS were similar in both groups. [3] In patients who receive first-line therapy with TKIs, the rate of decline in BCR-ABL...
when present on their own, were predicted to confer weaker But if the mutation rate in CP CML stem cells is so impressively high, why are relapse rates in CP patients so low?100 And why potency. The clinical relevance of newly detected mutations in the are relapses in this clinical ...
The Sokal index predicts survivalbased characteristics such as the patient’s age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood. Depending on the Sokal score, patients are classified as having low-risk, intermediate-risk, or highrisk CML, w...
To date, 200 "first generation" autologous transplantsfor the treatment of CML have been performed at eight centersin Europe and North America. In this group of patients, the survivalrate (at a median of 4 years post-transplant) for those with chronicphase CML was 59%, Dr. McGlave reporte...
likely because of their potent efficacy and the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. All four TKIs are equivalent if the aim of therapy is to improve survival. In younger patients with high‐risk disease and in wh...
Clinical parameters such as older age, low red cell and platelet counts, high lactate dehydrogenase, myeloid immunophenotype, and other features associated with poorer survival or higher risk of treatment failure that can be systematically evaluated in adults have no known correlates in children because...
Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 20(4):1179–1186 ...
In addition, patients receiving nilotinib demonstrated a lower rate of progression to the accelerated or blast stage of CML. Also in this study, the 5-year OS and PFS were similar in both groups. [3] In patients who receive first-line therapy with TKIs, the rate of decline in BCR-ABL...
The first study (Inchiosa Jr and Smith, 1990) only evaluated survival, whereas the effect of glucocorticoids on DOX toxicity was only evaluated in vitro (Chen et al, 2005). At present, our study quantifies to what extent cardioprotection occurred in animals cotreated with DEX, KP and mono...
In CKD, the higher levels of AGEs result from both increased formation and decreased renal clearance and may be related to survival [1]. AGEs contribute to the development and progression of CKD, and, conversely, the disease further promotes AGEs formation by inducing oxidative stress [2]. ...